MA27000A1 - Combinaison comprenant des agents combretastatins et anti cancereux. - Google Patents

Combinaison comprenant des agents combretastatins et anti cancereux.

Info

Publication number
MA27000A1
MA27000A1 MA27301A MA27301A MA27000A1 MA 27000 A1 MA27000 A1 MA 27000A1 MA 27301 A MA27301 A MA 27301A MA 27301 A MA27301 A MA 27301A MA 27000 A1 MA27000 A1 MA 27000A1
Authority
MA
Morocco
Prior art keywords
combination
cancer agents
combretastatin
anti cancer
agents
Prior art date
Application number
MA27301A
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MA27000A1 publication Critical patent/MA27000A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

DEMANDE DE BREVET COMBINAISON COMPRENANT DE LA COMBRESTATINE ET DES AGENTS ANTICANCEREUX AVENTIS PHARMA S.A. Une combinaison antitumorale comprenant un dérivé de stilbène et un composé anticancéreux choisi parmi le groupe constitué par des taxanes, des agents alkylants, des antimétabolites, des vinca-alcaloïdes, des épipodophyllotoxines et des antibiotiques en tant que principes actifs est fournie. Sont également fournis des procédés d'utilisation de ces préparations pharmaceutiques pour le traitement de carcinomes solides et analogues.
MA27301A 2001-03-15 2003-09-09 Combinaison comprenant des agents combretastatins et anti cancereux. MA27000A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27562701P 2001-03-15 2001-03-15

Publications (1)

Publication Number Publication Date
MA27000A1 true MA27000A1 (fr) 2004-12-20

Family

ID=23053164

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27301A MA27000A1 (fr) 2001-03-15 2003-09-09 Combinaison comprenant des agents combretastatins et anti cancereux.

Country Status (37)

Country Link
US (4) US20020183266A1 (fr)
EP (1) EP1439839B8 (fr)
JP (1) JP4991107B2 (fr)
KR (1) KR100849610B1 (fr)
CN (2) CN1290504C (fr)
AR (1) AR032989A1 (fr)
AT (1) ATE433750T1 (fr)
AU (1) AU2002304574B2 (fr)
BR (1) BR0208017A (fr)
CA (2) CA2470484C (fr)
CY (1) CY1109364T1 (fr)
CZ (1) CZ302451B6 (fr)
DE (1) DE60232673D1 (fr)
DK (1) DK1439839T3 (fr)
EA (1) EA006316B1 (fr)
EC (1) ECSP034766A (fr)
ES (1) ES2327617T3 (fr)
HR (1) HRPK20030734B3 (fr)
HU (1) HU228510B1 (fr)
IL (2) IL157891A0 (fr)
MA (1) MA27000A1 (fr)
ME (2) MEP16208A (fr)
MX (1) MXPA03007552A (fr)
NO (1) NO332661B1 (fr)
NZ (1) NZ527526A (fr)
PE (1) PE20020909A1 (fr)
PL (1) PL205728B1 (fr)
PT (1) PT1439839E (fr)
RS (1) RS50682B (fr)
SI (1) SI1439839T1 (fr)
SK (1) SK287908B6 (fr)
TN (1) TNSN03060A1 (fr)
TW (1) TWI306028B (fr)
UA (1) UA75127C2 (fr)
UY (1) UY27208A1 (fr)
WO (2) WO2004037258A1 (fr)
ZA (1) ZA200306789B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100598474B1 (ko) * 1998-04-03 2006-07-11 아지노모토 가부시키가이샤 항종양제
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
GB0410817D0 (en) * 2004-05-14 2004-06-16 Angiogene Pharm Ltd Vascular damaging therapy
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN1319978C (zh) * 2005-04-06 2007-06-06 西南合成制药股份有限公司 康布瑞汀化合物的制备方法
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US20080104512A1 (en) * 2006-10-31 2008-05-01 Motorola, Inc. Method and apparatus for providing realtime feedback in a voice dialog system
US20090264382A1 (en) * 2007-11-21 2009-10-22 David Chaplin Methods for Treating Hematopoietic Neoplasms
WO2009103076A1 (fr) * 2008-02-15 2009-08-20 Oxigene, Inc. Méthodes et compositions pour améliorer l'efficacité des inhibiteurs des récepteurs tyrosine kinases (rtk)
FR2939665B1 (fr) * 2008-12-12 2011-10-07 Sanofi Aventis Combinaison antitumorale associant l'ave8062a et le docetaxel
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EP2397135A1 (fr) 2010-06-18 2011-12-21 Sanofi Combinaison antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
EP2481404A1 (fr) 2010-11-15 2012-08-01 Sanofi Combinaison antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
BR112012031917A2 (pt) 2010-06-18 2017-11-28 Sanofi Sa combinação antitumoral compreendendo ombrabulina, um derivado de taxano e um derivado de platina
EP2407161A1 (fr) 2010-07-13 2012-01-18 Sanofi Combinaison antitumorale comprenant de l'ombrabuline et du bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
KR100598474B1 (ko) * 1998-04-03 2006-07-11 아지노모토 가부시키가이샤 항종양제
US6242770B1 (en) * 1998-08-31 2001-06-05 Gary Bela Bronner Diode connected to a magnetic tunnel junction and self aligned with a metallic conductor and method for forming the same
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
US6448030B1 (en) * 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
IL155509A0 (en) * 2000-10-27 2003-11-23 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
WO2002056692A1 (fr) * 2000-12-22 2002-07-25 Bristol-Myers Squibb Company Procedes relatifs a la modulation de la croissance tumorale et de la metastase
US6466448B1 (en) * 2001-06-11 2002-10-15 Network Appliance, Inc. Riser board retaining and air ducting structure for printed circuit boards

Also Published As

Publication number Publication date
JP4991107B2 (ja) 2012-08-01
ZA200306789B (en) 2005-02-23
EP1439839A1 (fr) 2004-07-28
CN1935134B (zh) 2010-12-15
PE20020909A1 (es) 2002-12-09
CA2673449A1 (fr) 2004-05-06
US20050075295A1 (en) 2005-04-07
IL157891A0 (en) 2004-03-28
NO20034022D0 (no) 2003-09-11
HU228510B1 (en) 2013-03-28
EP1439839B1 (fr) 2009-06-17
ES2327617T3 (es) 2009-11-02
US20030060429A1 (en) 2003-03-27
US20070149476A1 (en) 2007-06-28
HK1067039A1 (en) 2005-04-01
UY27208A1 (es) 2002-08-30
CN1935134A (zh) 2007-03-28
KR20040067866A (ko) 2004-07-30
MEP16208A (en) 2010-06-10
WO2004037258A1 (fr) 2004-05-06
CA2470484A1 (fr) 2004-05-06
PT1439839E (pt) 2009-09-03
HUP0600233A3 (en) 2010-03-29
EP1439839B8 (fr) 2010-09-01
JP2005522527A (ja) 2005-07-28
NZ527526A (en) 2006-11-30
WO2002074229A2 (fr) 2002-09-26
UA75127C2 (en) 2006-03-15
SK11552003A3 (sk) 2004-03-02
AU2002304574B2 (en) 2005-09-15
BR0208017A (pt) 2004-12-07
ATE433750T1 (de) 2009-07-15
CY1109364T1 (el) 2014-07-02
ECSP034766A (es) 2003-10-28
TNSN03060A1 (en) 2005-12-23
CZ20032476A3 (en) 2004-07-14
US20020183266A1 (en) 2002-12-05
PL205728B1 (pl) 2010-05-31
RS50682B (sr) 2010-06-30
DK1439839T3 (da) 2009-10-05
CN1547471A (zh) 2004-11-17
CN1290504C (zh) 2006-12-20
CZ302451B6 (cs) 2011-05-25
AU2002304574A1 (en) 2004-05-13
SI1439839T1 (sl) 2011-09-30
HRP20030734A2 (en) 2005-06-30
HRPK20030734B3 (en) 2006-11-30
EA200301015A1 (ru) 2004-08-26
CA2470484C (fr) 2009-10-13
YU71303A (sh) 2006-08-17
HUP0600233A2 (en) 2008-06-30
CA2673449C (fr) 2011-10-18
US6933320B2 (en) 2005-08-23
NO20034022L (no) 2003-09-11
EA006316B1 (ru) 2005-10-27
KR100849610B1 (ko) 2008-07-31
MXPA03007552A (es) 2004-10-15
NO332661B1 (no) 2012-11-26
DE60232673D1 (de) 2009-07-30
AR032989A1 (es) 2003-12-03
PL374406A1 (en) 2005-10-17
ME00056B (me) 2010-06-10
IL157891A (en) 2010-06-16
SK287908B6 (sk) 2012-03-02
TWI306028B (en) 2009-02-11

Similar Documents

Publication Publication Date Title
RU2217432C2 (ru) Эктеинасцидины, фармацевтическая композиция, содержащая их и способ лечения опухолей
EP1007044A4 (fr) Compositions pharmaceutiques contenant de la quinazolinone et destinees a la prevention de la neoformation de vaisseaux sanguins et au traitement d'affections malignes
IS6329A (is) Lyf til að meðhöndla illkynja æxli
MA27908A1 (fr) Agents therapeutiques utiles pour le traitement de la douleur
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
BR0210391A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
MA26877A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
CY1109364T1 (el) Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
PT934065E (pt) Compostos farmaceuticos
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
CA2269895A1 (fr) Utilisation d'un extrait flavonoidique de ginkgo biloba substantiellement depourvu de terpenes, dans le domaine bucco-dentaire, et composition contenant un tel extrait
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
SE9303853L (sv) Användning av en inositoltrisfosfatester för beredning av läkemedel
WO2005044175A3 (fr) Desensibilisation de l'activation du complement a l'aide de composes inhibiteurs de monocytes/macrophages
ATE233745T1 (de) Arzneistoffe
EP0850062A4 (fr) Compositions pharmaceutiques contenant de la quinazolinone, et prevenant la neo-vascularisation et permettant le traitement de tumeurs malignes humaines
RU99118510A (ru) Композиция для лечения или предупреждения рака простаты
MA27798A1 (fr) DERIVES DE BENZIMIDAZOLE COMME INHIBITEURS DU FACTEUR Xa